Brief: Cue Biopharma Presents New Positive Data From Ongoing Phase 1 Trial Of Cue-101 In Combination With Keytruda R

Cue Biopharma

10/11/2022 16:27

Nov 10 (Reuters) - Cue Biopharma Inc  CUE.O :
    * CUE BIOPHARMA PRESENTS NEW POSITIVE DATA FROM ONGOING
PHASE 1
TRIAL OF CUE-101 IN COMBINATION WITH KEYTRUDA(R) FOR
RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER AT THE SOCIETY
FOR IMMUNOTHERAPY OF CANCER’S (SITC) 37TH ANNUAL MEETING
    * CUE BIOPHARMA INC - ON TRACK TO DEFINE POTENTIAL
REGISTRATIONAL
CUE-101 MONOTHERAPY TRIAL BY MID-2023
    * CUE BIOPHARMA PRESENTS NEW POSITIVE DATA FROM ONGOING
PHASE 1
TRIAL OF CUE-101 IN COMBINATION WITH KEYTRUDA(R) FOR
RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER AT THE SOCIETY
FOR IMMUNOTHERAPY OF CANCER’S (SITC) 37TH ANNUAL MEETING
    * CUE BIOPHARMA INC - CUE-101 CONTINUED TO SHOW A FAVORABLE
TOLERABILITY PROFILE BOTH AS MONOTHERAPY AND IN COMBINATION WITH
PEMBROLIZUMAB
    * CUE BIOPHARMA INC - OVERALL RESPONSE RATE OF 40% AND A
CLINICAL
BENEFIT RATE OF 70% OBSERVED TO DATE IN STUDY

Source text for Eikon:  ID:nGNXcRXJB 
Further company coverage:  CUE.O 
 ((reuters.briefs@thomsonreuters.com;))